iifl-logo-icon 1

Jubilant Pharmova Ltd Half Yearly Results

920.45
(-4.16%)
Feb 14, 2025|01:09:58 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

3,462.6

3,411.6

3,233.2

3,194.1

3,025.2

Excise Duty

0

0

0

0

0

Net Sales

3,462.6

3,411.6

3,233.2

3,194.1

3,025.2

Other Operating Income

21.4

24.1

34

36.4

26

Other Income

417.4

66.7

26.1

26.2

24.4

Total Income

3,901.4

3,502.4

3,293.3

3,256.7

3,075.6

Total Expenditure

2,943.2

3,115.2

2,855.8

2,862.6

2,699.7

PBIDT

958.2

387.2

437.5

394.1

375.9

Interest

132

144.3

128

106.3

81.9

PBDT

826.2

242.9

309.5

287.8

294

Depreciation

182.1

195.6

186.3

365.5

188.5

Minority Interest Before NP

0

0

0

0

0

Tax

66.1

153.2

49.4

49.6

131.5

Deferred Tax

-6.3

-110.5

5.7

-10.7

-77.7

Reported Profit After Tax

584.3

4.6

68.1

-116.6

51.7

Minority Interest After NP

-0.6

-3.6

-0.8

-3.1

-0.8

Net Profit after Minority Interest

584.9

8.2

68.9

-113.5

52.5

Extra-ordinary Items

342.53

-168.9

0

0

14

Adjusted Profit After Extra-ordinary item

242.37

177.1

68.9

-113.5

38.5

EPS (Unit Curr.)

36.91

0.52

4.34

0

3.3

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

15.8

15.8

15.8

15.9

15.9

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

27.67

11.34

13.53

12.33

12.42

PBDTM(%)

-

-

-

-

-

PATM(%)

16.87

0.13

2.1

-3.65

1.7

Jubilant Pharmo: Related NEWS

Jubilant Pharmova Passes FDA Audit, Expands R&D with Pierre Fabre
26 Sep 2024|07:42 PM

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

Read More
FDA Issues VAI Status to Jubilant HollisterStier's Washington Facility
11 Sep 2024|11:23 AM

Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.

Read More
Top 10 stocks for today – 11th September, 2024
11 Sep 2024|09:23 AM

Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.

Read More
Jubilant Pharmova arm to pick up 80% stake in Pierre Fabre’s centre
19 Aug 2024|01:36 PM

Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.